The article reflects the results of a number of studies that demonstrate the therapeutic effectiveness of Recognan (citicoline) in anxiety-depressive and asthenic disorders against the background of somatic and neurological diseases, in the correction of post-stroke depression. Recent experimental animal studies prove the effect of citicoline on anxiety and depression. In the complex effect, Recognan potentiates the main pharmacological effect of antidepressants and anxiolytics. In some studies, a dose-dependent change in animal behavior has been observed in response to the analgesic and antidepressant effects of citicoline. The effectiveness of citicoline in combination with transcranial direct current stimulation in the treatment of depression has been shown. The analysis of these research materials allows us to recommend Recognan in the complex therapy of asthenic and anxiety-depressive disorders in response to such pathological conditions as anxiety, asthenia, depression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro202412406143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Factors affecting the quality of life of patients with neurological manifestations of post-COVID syndrome].
Zh Nevrol Psikhiatr Im S S Korsakova
October 2024
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Article Synopsis
- The study aimed to identify factors affecting the quality of life (QoL) in patients experiencing neurological symptoms from post-COVID syndrome (PCS) after recovering from COVID-19.
- It involved 60 patients, with 40 having additional symptoms such as fatigue and anxiety, while 20 had only their previous conditions without PCS complications.
- Results showed that factors like age over 40, high anxiety, and depressive symptoms significantly lowered QoL, emphasizing the need for improved treatment focusing on mental health issues in rehabilitation.
[Recognan (citicoline) prescribing in cerebrovascular diseases and type 2 diabetes mellitus patients].
Zh Nevrol Psikhiatr Im S S Korsakova
October 2024
International University of Restorative Medicine, Moscow, Russia.
In a number of clinical studies, Recognan (citicoline) has demonstrated its effectiveness in patients with ischemic stroke, traumatic brain injury, cognitive disorders of various origins, in the complex therapy of asthenic and anxiety-depressive disorders, showing neuroprotective and neuropreparative properties. In recent years, emphasis has been placed on citicoline appointment in the complex therapy of patients with type 2 diabetes mellitus (DM2). In experimental (induced DM2) and clinical studies of patients with cerebrovascular diseases (CVD) and DM2, the effectiveness of Recogan (citicoline) against diabetic retinopathy and diabetic polyneuropathy in more significant clinical changes and negative dynamics absence of important laboratory parameters (blood glucose levels) in acute and stroke recovery periods in patients with DM2.
View Article and Find Full Text PDF[Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders].
Zh Nevrol Psikhiatr Im S S Korsakova
July 2024
International University of Restorative Medicine, Moscow, Russia.
The article reflects the results of a number of studies that demonstrate the therapeutic effectiveness of Recognan (citicoline) in anxiety-depressive and asthenic disorders against the background of somatic and neurological diseases, in the correction of post-stroke depression. Recent experimental animal studies prove the effect of citicoline on anxiety and depression. In the complex effect, Recognan potentiates the main pharmacological effect of antidepressants and anxiolytics.
View Article and Find Full Text PDFAnxiety and Depression in Patients With Chronic Respiratory Diseases in the Fès-Meknès Region of Morocco.
Cureus
November 2023
Epidemiology, Clinical Research and Public Health, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, MAR.
Background Chronic respiratory diseases (CRDs) are a major public health problem in Morocco. Several studies have shown that anxiety and depression are important comorbidities of CRDs and are often associated with CRDs. This study aimed to estimate the prevalence of depression and anxiety and identify their determinants in patients with CRDs.
View Article and Find Full Text PDFAorto-mesenteric compass syndrome (Wilkie's syndrome) in the differential diagnosis of chronic abdominal pain.
BMJ Case Rep
September 2023
Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
A woman in her 40s was admitted to hospital with weight loss, asthenia, persistent abdominal pain and post-prandial nausea and vomiting. Other comorbidities were anxiety-depressive disorder, gastro-oesophageal reflux disease and fibrocystic mastopathy. On admission her body mass index (BMI) was 15.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!